Welcome to our dedicated page for Vertex Pharmaceuticals SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Vertex Pharmaceuticals filings document the biotechnology company’s operating results, governance and product-development disclosures. Recent Form 8-K reports include quarterly and annual results releases, selected regulatory and pipeline events involving therapies such as povetacicept, and officer or director transition disclosures.
The company’s proxy materials cover board composition, director nominees, shareholder meeting matters, executive compensation and equity-award information. Vertex filings also provide formal records for disclosure topics tied to its approved medicines, clinical pipeline and governance structure as a Nasdaq-listed operating company.
Ourania Tatsis has filed a Form 144 to sell 466 shares of common stock. The shares were acquired through restricted stock vesting on 02/10/2026 as compensation and are planned to be sold around 02/11/2026 through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of $214,560.38.
In the prior three months, Tatsis sold 4,500 common shares on 12/03/2025 for gross proceeds of $2,024,955.40 and another 4,500 shares on 01/07/2026 for $2,137,455.00.
Vertex Pharmaceuticals executive Mark E. Bunnage has filed an initial insider ownership report. As of February 1, 2026, he beneficially owns 16,062 shares of Vertex common stock, held directly. He serves as EVP, Chief Scientific Officer and reports no derivative securities in this filing.
Vertex Pharmaceuticals executive Charles F. Wagner Jr., EVP, CO & FO, reported the acquisition of 13,600 shares of Vertex common stock through earned performance awards. On 01/22/2026, he received 9,440 shares tied to a performance stock unit award granted on 02/01/2023 and 4,160 shares from a performance stock unit award granted on 02/12/2025, both at a price of $0 per share.
The company’s management development and compensation committee certified the performance-goal attainment on 01/22/2026. The 2023 award shares will vest on 02/13/2026, while the 2025 award shares will vest in installments beginning on 02/24/2026. Following these transactions, Wagner directly holds 51,325 shares of Vertex common stock.
Vertex Pharmaceuticals executive Ourania Tatsis reported awards of company stock tied to performance goals. On January 22, 2026, she acquired 7,866 shares of Vertex common stock at $0 per share as earned performance shares from a performance stock unit award originally granted on February 1, 2023. On the same date, she also acquired 3,883 shares at $0 per share as earned performance shares from a separate performance stock unit award granted on February 12, 2025. These awards were triggered after the company’s management development and compensation committee certified that the required performance goals had been met, with the 2023 grant scheduled to vest on February 13, 2026 and the 2025 grant scheduled to vest in installments beginning on February 24, 2026. Following these transactions, Tatsis directly beneficially owned 54,042 shares of Vertex common stock.
Vertex Pharmaceuticals executive Amit Sachdev reported new stock awards tied to performance goals. On 01/22/2026, he acquired 7,866 shares of Vertex common stock and another 3,883 shares at a price of $0 per share, reflecting earned performance stock unit awards granted on 02/01/2023 and 02/12/2025 after the compensation committee certified goal attainment on 01/22/2026. Following these awards, he directly holds 70,998 common shares, with additional indirect holdings of 882 shares in a 401(k) plan and 9,301 shares held in trust. The earned performance shares are scheduled to vest on 02/13/2026 and in installments beginning on 02/24/2026.
Vertex Pharmaceuticals executive McKechnie Duncan reported stock awards tied to performance goals. On 01/22/2026, Duncan acquired 4,720 shares of Vertex common stock at a price of $0 following the earning of performance shares from a performance stock unit award granted on 02/01/2023. After this transaction, Duncan directly owned 20,858 shares of common stock.
On the same date, Duncan also acquired 2,080 additional shares of Vertex common stock at a price of $0, representing earned performance shares from a performance stock unit award granted on 02/12/2025, bringing direct ownership to 22,938 shares. The issuer's management development and compensation committee certified the level of performance-goal attainment on 01/22/2026. The shares from the 2023 award will vest on 02/13/2026, and the shares from the 2025 award will vest in installments beginning on 02/24/2026.
Vertex Pharmaceuticals Executive Chairman Jeffrey M. Leiden reported the grant of 9,012 shares of common stock on January 22, 2026. The shares were acquired at a price of $0 as earned performance shares from a performance stock unit award originally granted on February 12, 2025, which was subject to performance-vesting conditions.
The company’s management development and compensation committee certified the level of performance-goal attainment on January 22, 2026, and these shares are scheduled to vest on February 24, 2026. Following this grant, Leiden beneficially owns 33,039 shares of Vertex common stock directly, plus 440 additional shares held indirectly through a 401(k) plan.
Vertex Pharmaceuticals CEO and President Reshma Kewalramani reported two stock acquisitions tied to performance awards. On 01/22/2026, she acquired 26,972 shares of common stock at $0, representing earned performance shares from a performance stock unit award granted on 02/01/2023 after the compensation committee certified performance-goal attainment. These shares will vest on 02/13/2026, bringing her direct holdings to 142,940 shares.
On the same date, she acquired 11,885 additional common shares at $0 as earned performance shares from a separate performance stock unit award granted on 02/12/2025, also following committee certification of performance-goal attainment. These shares will vest in installments beginning on 02/24/2026, increasing her directly held common stock to 154,825 shares.
Vertex Pharmaceuticals executive Carmen Bozic reported stock awards tied to prior performance-based grants. On 01/22/2026 she acquired 7,866 shares of common stock at $0, increasing her directly held stake to 40,535 shares. On the same date she acquired an additional 3,467 common shares at $0, bringing her directly held total to 44,002 shares.
The first block of 7,866 shares represents earned performance shares from a performance stock unit award granted on 02/01/2023, with shares scheduled to vest on 02/13/2026. The 3,467 shares represent earned performance shares from a performance stock unit award granted on 02/12/2025, with shares scheduled to vest in installments beginning on 02/24/2026.
Vertex Pharmaceuticals executive Jonathan Biller reported the acquisition of 9,068 shares of common stock through earned performance awards. On 01/22/2026, he received 6,294 shares tied to a performance stock unit grant from 02/01/2023 and 2,774 shares tied to a grant from 02/12/2025, both at a price of $0 per share. The company’s management development and compensation committee certified performance attainment on 01/22/2026. The first block of shares is scheduled to vest on 02/13/2026, and the second will vest in installments beginning on 02/24/2026. Following these awards, Biller directly beneficially owns 24,374 shares of Vertex common stock.